
Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities researchers at Cantor Fitzgerald cut their FY2026 earnings per share (EPS) estimates for Precigen in a report issued on Tuesday, August 19th. Cantor Fitzgerald analyst J. Kim now forecasts that the biotechnology company will post earnings of $0.07 per share for the year, down from their prior forecast of $0.11. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.
A number of other equities analysts also recently commented on the company. Citigroup reiterated an "outperform" rating on shares of Precigen in a research report on Tuesday, August 19th. HC Wainwright reiterated a "buy" rating and set a $8.50 price objective on shares of Precigen in a research report on Tuesday, August 19th. Wall Street Zen upgraded Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. JMP Securities lifted their price objective on Precigen from $6.00 to $8.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. upgraded Precigen from an "underweight" rating to a "neutral" rating in a research report on Friday, August 15th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $8.25.
View Our Latest Report on PGEN
Precigen Stock Performance
Shares of NASDAQ:PGEN traded down $0.0210 during trading on Wednesday, reaching $4.1590. The stock had a trading volume of 5,891,514 shares, compared to its average volume of 3,634,508. Precigen has a 1-year low of $0.65 and a 1-year high of $4.30. The stock has a market cap of $1.24 billion, a PE ratio of -9.94 and a beta of 1.87. The business has a fifty day moving average price of $1.87 and a 200-day moving average price of $1.67.
Precigen (NASDAQ:PGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.67 million. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.
Institutional Investors Weigh In On Precigen
Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in shares of Precigen in the 4th quarter valued at $27,000. Envestnet Asset Management Inc. raised its holdings in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after buying an additional 5,915 shares during the period. Apella Capital LLC purchased a new stake in shares of Precigen in the 1st quarter valued at $40,000. Boothbay Fund Management LLC purchased a new stake in shares of Precigen in the 4th quarter valued at $35,000. Finally, Voya Investment Management LLC raised its holdings in shares of Precigen by 142.9% in the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock valued at $55,000 after buying an additional 21,633 shares during the period. Hedge funds and other institutional investors own 33.51% of the company's stock.
About Precigen
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Featured Articles

Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.